AstraZeneca (AZN) PT Set at GBX 6,100 by Jefferies Financial Group
AstraZeneca (LON:AZN) has been given a GBX 6,100 ($79.71) target price by analysts at Jefferies Financial Group in a report issued on Thursday. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would suggest a potential downside of 2.26% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. lifted their target price on shares of AstraZeneca from GBX 6,900 ($90.16) to GBX 7,100 ($92.77) and gave the stock an “overweight” rating in a research report on Wednesday, January 2nd. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, February 5th. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a research report on Tuesday, November 6th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the company a “sell” rating in a research report on Friday, November 16th. Finally, Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, December 7th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca presently has a consensus rating of “Buy” and an average target price of GBX 6,222.20 ($81.30).
LON:AZN opened at GBX 6,241 ($81.55) on Thursday. AstraZeneca has a 12 month low of GBX 4,260 ($55.66) and a 12 month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.